This Article Full Text Full Text (PDF) Supplementary Data Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xue, C. Articles by Segall, J. E. Search for Related Content PubMed PubMed Citation Articles by Xue, C. Articles by Segall, J. E.

Epidermal Growth Factor Receptor Overexpression Results in Increased Tumor Cell Motility In vivo Coordinately with Enhanced Intravasation and Metastasis

Departments of ¹ Anatomy and Structural Biology and ² Molecular Pharmacology and ³ Analytical Imaging Facility, Albert Einstein College of Medicine, Bronx, New York

Requests for reprints: Jeffrey E. Segall, Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-4237; Fax: 718-430-8996; E-mail: segall{at}aecom.yu.edu.

Although overexpression of the epidermal growth factor receptor (EGFR; ErbB1) has been correlated with poor prognosis in breast and other cancers, clinical trials of ErbB1 inhibitors have shown limited efficacy in inhibiting tumor proliferation. To evaluate other possible roles of ErbB1 in tumor malignancy besides proliferation, we have developed a series of tools for analysis of intravasation. Overexpression of ErbB1 in MTLn3 mammary adenocarcinoma cells results in increased intravasation and lung metastasis from tumors formed by injection of cells in the mammary fat pad. However, increased ErbB1 expression has no effect on primary tumor growth and lung seeding efficiency of cells injected i.v. Chemotactic responses to low concentrations of EGF in vitro and cell motility in vivo in the primary tumor measured using intravital imaging are significantly increased by ErbB1 overexpression. The increased cell motility is restricted to ErbB1-overexpressing cells in tumors containing mixtures of cells expressing different ErbB1 levels, arguing for a cell-autonomous effect of increased ErbB1 expression rather than alteration of the tumor microenvironment. In summary, we propose that ErbB1 overexpression makes more significant contributions to intravasation than growth in some tumors and present a novel model for studying ErbB1 contributions to tumor metastasis via chemotaxis and intravasation. (Cancer Res 2006; 66(1): 192-7)

This article has been cited by other articles:

				S. Goldoni, D. G. Seidler, J. Heath, M. Fassan, R. Baffa, M. L. Thakur, R. T. Owens, D. J. McQuillan, and R. V. Iozzo An Antimetastatic Role for Decorin in Breast Cancer Am. J. Pathol., September 1, 2008; 173(3): 844 - 855. [Abstract] [Full Text] [PDF]

				J. van Rheenen, X. Song, W. van Roosmalen, M. Cammer, X. Chen, V. DesMarais, S.-C. Yip, J. M. Backer, R. J. Eddy, and J. S. Condeelis EGF-induced PIP2 hydrolysis releases and activates cofilin locally in carcinoma cells J. Cell Biol., December 17, 2007; 179(6): 1247 - 1259. [Abstract] [Full Text] [PDF]

				J. J. Partridge, M. A. Madsen, V. C. Ardi, T. Papagiannakopoulos, T. A. Kupriyanova, J. P. Quigley, and E. I. Deryugina Functional Analysis of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Differentially Expressed by Variants of Human HT-1080 Fibrosarcoma Exhibiting High and Low Levels of Intravasation and Metastasis J. Biol. Chem., December 7, 2007; 282(49): 35964 - 35977. [Abstract] [Full Text] [PDF]

				Y.-s. Wang, G.-q. Wang, Y.-j. Wen, L. Wang, X.-c. Chen, P. Chen, B. Kan, J. Li, C. Huang, Y. Lu, et al. Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine {beta}-Defensin 2 and mFlk-1 Clin. Cancer Res., November 15, 2007; 13(22): 6779 - 6787. [Abstract] [Full Text] [PDF]

				J. Pu, C. D. McCaig, L. Cao, Z. Zhao, J. E. Segall, and M. Zhao EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells J. Cell Sci., October 1, 2007; 120(19): 3395 - 3403. [Abstract] [Full Text] [PDF]

				Y. Sun, K. Ling, M. P. Wagoner, and R. A. Anderson Type I{gamma} phosphatidylinositol phosphate kinase is required for EGF-stimulated directional cell migration J. Cell Biol., July 10, 2007; 178(2): 297 - 308. [Abstract] [Full Text] [PDF]

				A. Zundelevich, G. Elad-Sfadia, R. Haklai, and Y. Kloog Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid) Mol. Cancer Ther., June 1, 2007; 6(6): 1765 - 1773. [Abstract] [Full Text] [PDF]

				F. Di Modugno, L. DeMonte, M. Balsamo, G. Bronzi, M. R. Nicotra, M. Alessio, E. Jager, J. S. Condeelis, A. Santoni, P. G. Natali, et al. Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena+11a Phosphorylation in Breast Cancer Cell Lines Cancer Res., March 15, 2007; 67(6): 2657 - 2665. [Abstract] [Full Text] [PDF]

				L. Bonaccorsi, D. Nosi, M. Muratori, L. Formigli, G. Forti, and E. Baldi Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines J. Mol. Endocrinol., January 1, 2007; 38(1): 51 - 66. [Abstract] [Full Text] [PDF]

				EGFR Enhances Motility and Intravasation In vivo Cancer Res., April 15, 2006; 66(8): 4547 - 4547. [Full Text] [PDF]